CL2018002814A1 - Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. - Google Patents

Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.

Info

Publication number
CL2018002814A1
CL2018002814A1 CL2018002814A CL2018002814A CL2018002814A1 CL 2018002814 A1 CL2018002814 A1 CL 2018002814A1 CL 2018002814 A CL2018002814 A CL 2018002814A CL 2018002814 A CL2018002814 A CL 2018002814A CL 2018002814 A1 CL2018002814 A1 CL 2018002814A1
Authority
CL
Chile
Prior art keywords
wounds
disorders
compositions
treatment
methods
Prior art date
Application number
CL2018002814A
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018002814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of CL2018002814A1 publication Critical patent/CL2018002814A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
CL2018002814A 2016-04-08 2018-10-03 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. CL2018002814A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
CL2018002814A1 true CL2018002814A1 (es) 2019-02-15

Family

ID=57822104

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018002814A CL2018002814A1 (es) 2016-04-08 2018-10-03 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2021000881A CL2021000881A1 (es) 2016-04-08 2021-04-09 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814
CL2023000743A CL2023000743A1 (es) 2016-04-08 2023-03-15 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2021000881A CL2021000881A1 (es) 2016-04-08 2021-04-09 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814
CL2023000743A CL2023000743A1 (es) 2016-04-08 2023-03-15 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel

Country Status (21)

Country Link
US (7) US9877990B2 (es)
EP (2) EP3712273A1 (es)
JP (3) JP6970086B2 (es)
KR (1) KR20180128016A (es)
CN (1) CN109072255A (es)
AU (3) AU2016401692B2 (es)
CA (1) CA3017487A1 (es)
CL (3) CL2018002814A1 (es)
CY (1) CY1123024T1 (es)
DK (1) DK3377637T3 (es)
ES (1) ES2796488T3 (es)
HR (1) HRP20200853T1 (es)
HU (1) HUE049237T2 (es)
LT (1) LT3377637T (es)
MX (2) MX2018012135A (es)
PL (1) PL3377637T3 (es)
PT (1) PT3377637T (es)
RS (1) RS60410B1 (es)
SG (1) SG11201808314QA (es)
SI (1) SI3377637T1 (es)
WO (1) WO2017176336A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
US9877990B2 (en) 2016-04-08 2018-01-30 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
CN110312506A (zh) * 2016-11-14 2019-10-08 密歇根大学董事会 用于阻挡紫外线辐射的组合物和方法
SG11201906213UA (en) * 2017-01-10 2019-08-27 Intrexon Corp Modulating expression of polypeptides via new gene switch expression systems
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2019252658B2 (en) 2018-04-12 2023-09-14 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
AU2019260757B2 (en) * 2018-04-27 2023-09-28 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
EP3856761A1 (en) * 2018-09-24 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
US20210395775A1 (en) 2018-09-26 2021-12-23 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
KR20210116531A (ko) * 2019-01-18 2021-09-27 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 영양 장애형 표피 수포증 치료약
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
US20220177546A1 (en) * 2019-03-27 2022-06-09 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
US20230118087A1 (en) 2019-09-03 2023-04-20 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
US20210189427A1 (en) 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
EP4314028A1 (en) 2021-04-02 2024-02-07 Krystal Biotech, Inc. Viral vectors for cancer therapy
CA3234797A1 (en) 2021-10-12 2023-04-20 Hal Landy Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
ES2303726T3 (es) * 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO1999064094A1 (en) * 1998-06-12 1999-12-16 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
EP1141338A4 (en) * 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
JP4004952B2 (ja) * 2000-11-28 2007-11-07 ザ ユニヴァーシティ オヴ シカゴ 心血管疾患治療のための遺伝的に操作されたヘルペスウイルス
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP1805213B1 (en) * 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2008528508A (ja) * 2005-01-21 2008-07-31 イントロジェン・セラピューティクス，インコーポレイテッド 標的細胞の治療および予防核酸への持続性の曝露を可能とする局所投与
WO2006130855A2 (en) * 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
EP2766480B1 (en) * 2011-10-11 2018-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) * 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
CA2902954A1 (en) * 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
PT2968586T (pt) * 2013-03-14 2018-11-13 Ethris Gmbh Composições de arnm de cftr e métodos e utilizações relacionados
EP3022307A4 (en) * 2013-07-17 2017-04-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
SG11201603119RA (en) * 2013-10-28 2016-05-30 Univ Pittsburgh Oncolytic hsv vector
MX2016009771A (es) 2014-01-31 2016-11-14 Factor Bioscience Inc Metodos y productos para la produccion y administracion de acido nucleico.
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
JP6925805B2 (ja) * 2014-10-31 2021-08-25 京都府公立大学法人 ラミニンによる角膜の新規治療
US20180148711A1 (en) * 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
EP3795180A1 (en) * 2015-12-14 2021-03-24 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
CN117143837A (zh) * 2016-03-25 2023-12-01 普瑞菲根公司 高转导hsv载体
CN109310728B (zh) * 2016-03-25 2022-08-12 普瑞菲根公司 用于递送nt3和治疗cipn的hsv载体
US9877990B2 (en) 2016-04-08 2018-01-30 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AU2019252658B2 (en) 2018-04-12 2023-09-14 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
AU2019260757B2 (en) 2018-04-27 2023-09-28 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
AU2019292580A1 (en) 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
CY1123024T1 (el) 2021-10-29
US9877990B2 (en) 2018-01-30
HUE049237T2 (hu) 2020-09-28
US20200101123A1 (en) 2020-04-02
KR20180128016A (ko) 2018-11-30
US20170290866A1 (en) 2017-10-12
US10155016B2 (en) 2018-12-18
CA3017487A1 (en) 2017-10-12
CN109072255A (zh) 2018-12-21
AU2016401692A1 (en) 2018-09-27
US20190160122A1 (en) 2019-05-30
PL3377637T3 (pl) 2020-09-07
SI3377637T1 (sl) 2020-08-31
JP2019513689A (ja) 2019-05-30
PT3377637T (pt) 2020-06-17
MX2022006072A (es) 2022-06-14
CL2023000743A1 (es) 2023-09-29
JP2023118838A (ja) 2023-08-25
CL2021000881A1 (es) 2021-09-10
JP6970086B2 (ja) 2021-11-24
EP3377637B1 (en) 2020-03-18
EP3377637A1 (en) 2018-09-26
ES2796488T3 (es) 2020-11-27
US10441614B2 (en) 2019-10-15
US11185564B2 (en) 2021-11-30
US20180169160A1 (en) 2018-06-21
DK3377637T3 (da) 2020-05-18
NZ746213A (en) 2021-08-27
LT3377637T (lt) 2020-07-10
US11865148B2 (en) 2024-01-09
MX2018012135A (es) 2019-03-28
HRP20200853T1 (hr) 2020-08-21
US20230149486A1 (en) 2023-05-18
AU2019280069B2 (en) 2022-04-07
EP3712273A1 (en) 2020-09-23
US20220273737A1 (en) 2022-09-01
WO2017176336A1 (en) 2017-10-12
RS60410B1 (sr) 2020-07-31
AU2022204729A1 (en) 2022-07-21
JP2022023174A (ja) 2022-02-07
US20230414686A1 (en) 2023-12-28
SG11201808314QA (en) 2018-10-30
AU2016401692B2 (en) 2019-10-03
AU2019280069A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
IL264049A (en) Compounds, preparations and methods for treating the disease
ES2965696T3 (es) Oligómeros antisentido para el tratamiento de afecciones y enfermedades
IL264156A (en) Compounds, preparations and methods for treating the disease
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2014003455A1 (es) Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PT3405215T (pt) Métodos para o tratamento da doença de danon e outros transtornos da autofagia
ES2966369T3 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
DK3307277T3 (da) Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser
IL274233A (en) Compounds, preparations and methods for the treatment of eye disorders and skin diseases
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
EP3558281A4 (en) TREATMENT OF MENTAL DISORDERS, MOVEMENT AND BEHAVIOR
IT201700121764A1 (it) Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative.
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
ITUB20160121A1 (it) Gabapentina oftalmica per il trattamento di ulcere corneali
IL259381B (en) Miravegron for the treatment of retinal diseases
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
ES2965877T3 (es) Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas
GB201604359D0 (en) Treatment of tissue disorders